Prescribing patterns of asthma treatment in the private healthcare sector of South Africa / Johannes Marthinus de Wet

Asthma is a chronic disease of the airways and affects many people regardless of their age, gender, race and socioeconomic status. Since asthma is recognised as one of the major causes of morbidity and mortality in people and especially in South Africa, the prescribing patterns, prevalence and medic...

Full description

Bibliographic Details
Main Author: De Wet, Johannes Marthinus
Language:en
Published: 2014
Subjects:
Online Access:http://hdl.handle.net/10394/10840
id ndltd-netd.ac.za-oai-union.ndltd.org-nwu-oai-dspace.nwu.ac.za-10394-10840
record_format oai_dc
collection NDLTD
language en
sources NDLTD
topic Asthma
South Africa
Drug utilisation review
Chronic obstructive pulmonary disease
Prescribing patterns
Prevalence
Cost of medications
Asma
Suid-Afrika
Medisyneverbruiksoorsig
Kroniese obstruktiewe pulmonêre siekte
Voorskrifpatrone
Voorkoms
Koste van medikasies
spellingShingle Asthma
South Africa
Drug utilisation review
Chronic obstructive pulmonary disease
Prescribing patterns
Prevalence
Cost of medications
Asma
Suid-Afrika
Medisyneverbruiksoorsig
Kroniese obstruktiewe pulmonêre siekte
Voorskrifpatrone
Voorkoms
Koste van medikasies
De Wet, Johannes Marthinus
Prescribing patterns of asthma treatment in the private healthcare sector of South Africa / Johannes Marthinus de Wet
description Asthma is a chronic disease of the airways and affects many people regardless of their age, gender, race and socioeconomic status. Since asthma is recognised as one of the major causes of morbidity and mortality in people and especially in South Africa, the prescribing patterns, prevalence and medication cost of asthma in South Africa are saliently important and need to be investigated. A non-experimental, quantitative retrospective drug utilisation review was conducted on medicine claims data of a pharmaceutical benefit management company in a section of the private health care sector of South Africa. The study period was divided into four annual time periods (1 January 2008 to 31 December 2008, 1 January 2009 to 31 December 2009, 1 January 2010 to 31 December 2010 and 1 January 2011 to 31 December 2011). The prescribing patterns and cost of asthma medication were investigated and stratified according to province, age and gender. Patients were included if the prescriptions which were provided by the health care practitioners matched the Chronic Disease List (CDL) of South Africa and the International Classification of Disease (ICD-10) coding for asthma and chronic obstructive pulmonary disease (COPD). Data analysis was conducted by means of the SAS 9.3® computer package. Asthma patients were divided according to different age groups (there were five different age groups for this study), gender and geographical areas of South Africa. The study indicated a steady increase in the prevalence of asthma patients from 0.82% (n = 7949) in 2008 to 1.18% (n = 15 423) in 2009 and reached a minimum of 0.79% (n = 8554) in 2011. Analysis of the prevalence regarding geographical areas in South Africa suggested that Gauteng had the highest number [n = 17 696, (0.85%)] of asthma patients throughout the study period, followed by KwaZulu Natal [n = 8 628, 1.16%)] and the Western Cape [(n = 8513, 0.97%) (p < 0.05)]. The prevalence of asthma in female patients [0.89% (n = 26 588)] was higher than in their male counterparts [0.79% (n = 19 244)] (p > 0.05). The results showed that asthma was not as common chronic disease in children. The total number of asthma patients younger than 7 years represented 0.64% (n = 2 909). It was found that patients over 65 years of age showed the highest prevalence of the five age groups [1.94% (n = 13 403) (p < 0.05)]. The average number of asthma prescriptions per patient per year was 8.28 (95% CI, 8.16- 8.40) and 5.15 (95% CI, 5.06-5.23) in 2008 and 2011, respectively. The number of asthma items per prescription varied from 1.55 (95% CI, 1.55-1.56) in 2008 to 1.40 (95% CI, 1.39- 1.40) in 2011. Medication from the MIMS® pharmacological group (anti-asthmatics and bronchodilators) was used to identify asthma medication. The top three asthma medication with the highest prevalence in the study period were the anti-inflammatory inhaler of fluticasone (n = 39 721) followed by the single item combination product of budesonide/ formoterol (n = 25 121) and salbutamol (n = 24 296). The influence of COPD on asthma treatment and the costimplication thereof were investigated. Medication from the MIMS® pharmacological group (anti-asthmatics and bronchodilators) was used to identify COPD medication. This study also showed that COPD had an influence in the economic burden of the South African asthma population. The cost of medication is responsible for the single largest direct cost involved in the economic burden of asthma. This study showed that asthma represented 0.88% of the direct medication cost in the study (excluding hospitalisation and indirect cost). The average cost per prescription and average cost per asthma item both increased throughout the study period. The prescribing patterns for the different medication used in the treatment of asthma were investigated and recommendations for further research in this field of study were made. === MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2014
author De Wet, Johannes Marthinus
author_facet De Wet, Johannes Marthinus
author_sort De Wet, Johannes Marthinus
title Prescribing patterns of asthma treatment in the private healthcare sector of South Africa / Johannes Marthinus de Wet
title_short Prescribing patterns of asthma treatment in the private healthcare sector of South Africa / Johannes Marthinus de Wet
title_full Prescribing patterns of asthma treatment in the private healthcare sector of South Africa / Johannes Marthinus de Wet
title_fullStr Prescribing patterns of asthma treatment in the private healthcare sector of South Africa / Johannes Marthinus de Wet
title_full_unstemmed Prescribing patterns of asthma treatment in the private healthcare sector of South Africa / Johannes Marthinus de Wet
title_sort prescribing patterns of asthma treatment in the private healthcare sector of south africa / johannes marthinus de wet
publishDate 2014
url http://hdl.handle.net/10394/10840
work_keys_str_mv AT dewetjohannesmarthinus prescribingpatternsofasthmatreatmentintheprivatehealthcaresectorofsouthafricajohannesmarthinusdewet
_version_ 1716715316055113728
spelling ndltd-netd.ac.za-oai-union.ndltd.org-nwu-oai-dspace.nwu.ac.za-10394-108402014-09-30T04:04:34ZPrescribing patterns of asthma treatment in the private healthcare sector of South Africa / Johannes Marthinus de WetDe Wet, Johannes MarthinusAsthmaSouth AfricaDrug utilisation reviewChronic obstructive pulmonary diseasePrescribing patternsPrevalenceCost of medicationsAsmaSuid-AfrikaMedisyneverbruiksoorsigKroniese obstruktiewe pulmonêre siekteVoorskrifpatroneVoorkomsKoste van medikasiesAsthma is a chronic disease of the airways and affects many people regardless of their age, gender, race and socioeconomic status. Since asthma is recognised as one of the major causes of morbidity and mortality in people and especially in South Africa, the prescribing patterns, prevalence and medication cost of asthma in South Africa are saliently important and need to be investigated. A non-experimental, quantitative retrospective drug utilisation review was conducted on medicine claims data of a pharmaceutical benefit management company in a section of the private health care sector of South Africa. The study period was divided into four annual time periods (1 January 2008 to 31 December 2008, 1 January 2009 to 31 December 2009, 1 January 2010 to 31 December 2010 and 1 January 2011 to 31 December 2011). The prescribing patterns and cost of asthma medication were investigated and stratified according to province, age and gender. Patients were included if the prescriptions which were provided by the health care practitioners matched the Chronic Disease List (CDL) of South Africa and the International Classification of Disease (ICD-10) coding for asthma and chronic obstructive pulmonary disease (COPD). Data analysis was conducted by means of the SAS 9.3® computer package. Asthma patients were divided according to different age groups (there were five different age groups for this study), gender and geographical areas of South Africa. The study indicated a steady increase in the prevalence of asthma patients from 0.82% (n = 7949) in 2008 to 1.18% (n = 15 423) in 2009 and reached a minimum of 0.79% (n = 8554) in 2011. Analysis of the prevalence regarding geographical areas in South Africa suggested that Gauteng had the highest number [n = 17 696, (0.85%)] of asthma patients throughout the study period, followed by KwaZulu Natal [n = 8 628, 1.16%)] and the Western Cape [(n = 8513, 0.97%) (p < 0.05)]. The prevalence of asthma in female patients [0.89% (n = 26 588)] was higher than in their male counterparts [0.79% (n = 19 244)] (p > 0.05). The results showed that asthma was not as common chronic disease in children. The total number of asthma patients younger than 7 years represented 0.64% (n = 2 909). It was found that patients over 65 years of age showed the highest prevalence of the five age groups [1.94% (n = 13 403) (p < 0.05)]. The average number of asthma prescriptions per patient per year was 8.28 (95% CI, 8.16- 8.40) and 5.15 (95% CI, 5.06-5.23) in 2008 and 2011, respectively. The number of asthma items per prescription varied from 1.55 (95% CI, 1.55-1.56) in 2008 to 1.40 (95% CI, 1.39- 1.40) in 2011. Medication from the MIMS® pharmacological group (anti-asthmatics and bronchodilators) was used to identify asthma medication. The top three asthma medication with the highest prevalence in the study period were the anti-inflammatory inhaler of fluticasone (n = 39 721) followed by the single item combination product of budesonide/ formoterol (n = 25 121) and salbutamol (n = 24 296). The influence of COPD on asthma treatment and the costimplication thereof were investigated. Medication from the MIMS® pharmacological group (anti-asthmatics and bronchodilators) was used to identify COPD medication. This study also showed that COPD had an influence in the economic burden of the South African asthma population. The cost of medication is responsible for the single largest direct cost involved in the economic burden of asthma. This study showed that asthma represented 0.88% of the direct medication cost in the study (excluding hospitalisation and indirect cost). The average cost per prescription and average cost per asthma item both increased throughout the study period. The prescribing patterns for the different medication used in the treatment of asthma were investigated and recommendations for further research in this field of study were made.MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 20142014-07-09T07:05:00Z2014-07-09T07:05:00Z2013Thesishttp://hdl.handle.net/10394/10840en